BioCardia, Inc. (BCDA) · Nov 20, 2026 · Delisting
Nasdaq deficiency — $835,000 equity vs $2.5 million requirement
BioCardia’s Nasdaq listing faces a new equity deficiency after stockholders’ equity fell to $835,000. The filing resets the capital-pressure story.
BioCardia is a clinical-stage cell-therapy company advancing its CardiAMP heart-failure program and related cardiovascular technologies, but it remains loss-making and dependent on external capital to fund development. Its latest quarterly filing said $2.2 million of cash was not sufficient to fund planned expenditures beyond January 2027 and raised substantial doubt about continuing as a going concern.
The Nasdaq problem has returned despite a prior equity cure. BioCardia previously raised about $4.9 million through its at-the-market offering and said that financing restored compliance with Nasdaq’s $2.5 million equity rule in June 2026; the company also separately faces a minimum-bid-price deficiency with a February 16, 2027 deadline. The new notice shows that the earlier fix did not hold through the September quarter: stockholders’ equity was only $835,000 against Nasdaq’s $2.5 million requirement.
| Metric | September 30, 2026 | Nasdaq requirement |
|---|---|---|
| Stockholders’ equity (Notice) | $835,000 | $2,500,000 |
This is more than a routine compliance notice because it tightens an already narrow funding window. The company must submit a recovery plan by January 4, 2027, while its latest quarterly report says existing cash may not last beyond January 2027. Nasdaq can grant up to 180 additional days if it accepts the plan, but acceptance is discretionary and the filing gives no committed financing or operational fix. 〔0〕
The immediate consequence is heightened execution and financing risk, not an immediate delisting. BioCardia still has a path through a compliance plan, a hearing request, and likely additional capital, but the company’s own disclosure makes clear that neither regaining compliance nor obtaining relief is assured. 〔1〕
Bottom line: This reopens a Nasdaq listing problem that BioCardia had only recently claimed to solve, while its cash runway is already short. It materially weakens the current financing-and-clinical-development story, even though delisting is not immediate.
Nasdaq compliance plan due January 4, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!